Tenaya Therapeutics (TNYA) Operating Expenses (2020 - 2026)

Tenaya Therapeutics has reported Operating Expenses for 7 years, with the latest figure at $20.3 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses fell 26.32% year-over-year to $20.3 million; the trailing twelve-month figure through Mar 2026 stood at $86.1 million (down 21.55% YoY), and the FY2025 full-year result was $93.3 million, down 19.51% from the prior year.
• Operating Expenses for Q1 2026 stood at $20.3 million, down from $20.8 million in the prior quarter.
• The five-year high for Operating Expenses was $35.1 million in Q2 2023, with the low at $20.3 million in Q1 2026.
• Average Operating Expenses over 5 years is $28.6 million, with a median of $30.8 million recorded in 2024.
• Year-over-year, Operating Expenses jumped 137.73% in 2022 and fell 26.32% in 2026.
• Tracing TNYA's Operating Expenses over 5 years: stood at $34.6 million in 2022, then decreased by 8.98% to $31.4 million in 2023, then dropped by 21.61% to $24.7 million in 2024, then slipped by 15.73% to $20.8 million in 2025, then dropped by 2.33% to $20.3 million in 2026.
• The last three Operating Expenses figures came in at $20.3 million (Q1 2026), $20.8 million (Q4 2025), and $20.9 million (Q3 2025), per Business Quant data.

Peer Comparison